"Ongoing translational analyses (including HRD and HRR evaluation, microRNA expression, and tumor microenvironment immunologic composition) will possibly help in identifying predictive biomarkers of response/resistance to trabectedin."

#Cancer #Kanser #OvarianCancer #BRCAness #Trabectedin

The phase III MITO-23 trial compared trabectedin monotherapy to physician’s choice chemo in 244 patients with BRCA-mutated or BRCAness recurrent ovarian cancer.

@ascocancer.bsky.social #JCO #ASCO

#Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials